Simcere Pharmaceutical Group Announces its Special Committee's Engagement of Financial Advisor

 Simcere Pharmaceutical Group Announces its Special Committee's Engagement of
                              Financial Advisor

PR Newswire

NANJING, China, April 3, 2013

NANJING, China, April 3, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group
("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company
specializing in the development, manufacturing, and marketing of branded and
proprietary pharmaceuticals in China, today announced that its Special
Committee of the Board of Directors (the "Special Committee"), which was
formed to consider a proposal by Mr. Jinsheng Ren, New Good Management
Limited, Assure Ahead Investments Limited and its affiliates (the "Buyer
Group"), pursuant to which the Buyer Group proposes to acquire all of the
outstanding ordinary shares of the Company not currently owned by the Buyer
Group, and any potential alternative transactions involving the Company, has
retained UBS AG and/or its affiliates as its exclusive financial advisor to
assist it in its work. No decisions have been made by the Special Committee
with respect to the Company's response to the proposed transaction. There can
be no assurance that any definitive offer will be made, that any agreement
will be executed or that this or any other transaction will be approved or
consummated.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR) is a
leading pharmaceutical company specializing in the development, manufacturing,
and marketing of branded and proprietary pharmaceuticals in China. Simcere
concentrates its research and development efforts on the treatment of diseases
with high incidence and/or mortality rates and for which there is a clear
demand for more effective pharmacotherapy such as cancer, strokes,
cardiovascular disease, infectious diseases and pain. For more information
about Simcere Pharmaceutical Group, please visit www.simcere.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements
constitute "forward-looking" statements within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended, and as defined in the U.S.
Private Securities Litigation Reform Act of 1995. These forward-looking
statements can be identified by terminology such as "anticipate," "believe,"
"estimate," "expect," "forecast," "intend," "may," "plan," "project,"
"predict," "should" and "will" and similar expressions. These statements are,
by their nature, subject to a number of risks and uncertainties that could
cause actual performance and results to differ materially from those discussed
in the forward-looking statements as a result of a number of factors. Further
information regarding these and other risks is included in Simcere's filings
with the U.S. Securities and Exchange Commission at www.sec.gov. Simcere does
not undertake any obligation to update any forward-looking statement, except
as required under applicable law.

Investor and Media Contacts:

Email: ir@simcere.com

In Nanjing:
                             In the United States:
Jie Liu D'Elia
                             Cindy Zheng
Vice President
                             Brunswick Group LLC
Simcere Pharmaceutical Group
                             Tel: 1-212-333-3810
Tel: 86-25-8556-6666*8857
In Beijing:

Yue Yu

Brunswick Group

Tel: 86-10-5960-8600

SOURCE Simcere Pharmaceutical Group

Website: http://www.simcere.com
 
Press spacebar to pause and continue. Press esc to stop.